Chemotherapy Induced Peripheral Neuropathy Market Size is Projected to Grow with a CAGR of 14.2% by 2036, estimates DelveInsight

The Chemotherapy-Induced Peripheral Neuropathy Market Size (7MM) was valued at ~USD 1000 Million in 2025 and is projected to grow at a significant CAGR by 2036. DelveInsight’s Comprehensive market research provides critical insights into such market trends, enabling stakeholders to understand growth drivers, emerging opportunities, and potential challenges within the Chemotherapy-Induced Peripheral Neuropathy Market Landscape. By analyzing historical data, current Chemotherapy-Induced Peripheral Neuropathy Market Dynamics, and future projections, DelveInsight equips pharmaceutical companies, investors, and healthcare professionals with actionable intelligence to make informed strategic decisions, identify investment opportunities, optimize product positioning, and plan research and development initiatives effectively.

The Chemotherapy-Induced Peripheral Neuropathy Market is increasingly guided by biomarker-driven strategies. Chemotherapy-Induced Peripheral Neuropathy is a common and often debilitating side effect of certain chemotherapy treatments, particularly those involving platinum compounds, taxanes, and vinca alkaloids. It occurs due to damage to the peripheral nerves, which are responsible for transmitting signals between the central nervous system and the rest of the body.

DelveInsight’s report, “Chemotherapy-Induced Peripheral Neuropathy Market Insights, Epidemiology, and Market Forecast-2036,” provides a comprehensive analysis of the Chemotherapy-Induced Peripheral Neuropathy Market landscape. The report delivers detailed insights into the disease, including historical and projected epidemiology, helping stakeholders understand the prevalence, incidence, and patient demographics across key regions. Additionally, it examines Chemotherapy-Induced Peripheral Neuropathy Market Dynamics, offering a thorough assessment of current and emerging market trends, treatment patterns, and therapeutic developments. The analysis spans major markets, including the United States, EU4 (Germany, Spain, Italy, France, and the United Kingdom), and Japan, equipping decision-makers with actionable intelligence for strategic planning, investment, and research initiatives.

To know in detail about the Chemotherapy-Induced Peripheral Neuropathy Market Outlook, drug uptake, treatment scenario, and epidemiology trends, click here @ https://www.delveinsight.com/report-store/cipn-market

Key Takeaways from Chemotherapy-Induced Peripheral Neuropathy Market Report

• According to DelveInsight’s estimates, in 2025, the total number of incident cases of CIPN in the 7MM was ~1.6 million.
• In the US, among severity-specific incident cases of CIPN, severe CIPN accounted for the majority of cases (~239,600), followed by mild (~208,550) and moderate (~199,500) in 2025.
• In 2025, breast and colorectal cancers accounted for the majority share of CIPN incidence across the EU4 and the UK. Breast cancer was associated with ~123,450 CIPN cases, and colorectal cancer contributed ~118,600 cases.
• The likelihood of developing CIPN is strongly influenced by the extent of chemotherapy use, with higher utilization seen in cancers such as hematologic malignancies, lung, and gastric cancers. This makes chemotherapy exposure, rather than cancer incidence alone, a critical determinant of CIPN burden. As treatment intensity and duration increase, the risk of neuropathy correspondingly rises
• The leading Chemotherapy-Induced Peripheral Neuropathy Companies such as Averitas Pharma (Grünenthal), Dogwood Therapeutics, AlgoTherapeutix, Sanodyne Therapeutics/Toray Industries, Sonnet BioTherapeutics, Asahi Kasei Pharma, WinSanTor, VM Therapeutics, Tarian Pharma and others.
• Promising Chemotherapy-Induced Peripheral Neuropathy Pipeline Therapies such as WST-05, ATX01 10%, Capsaicin, Duloxetine, Olesoxime (TRO19622), ONO-2910, VMD-3866 Gel, Acupuncture, Leteprinim Potassium (Neotrofin) and others.

Chemotherapy-Induced Peripheral Neuropathy Overview

Chemotherapy-Induced Peripheral Neuropathy is a dose-limiting toxicity associated with several commonly used anticancer agents, characterized by progressive sensory disturbances that often follow a “stocking-and-glove” distribution. The condition arises from chemotherapy-induced damage to peripheral nerve fibers, particularly affecting axonal transport and mitochondrial function. Patients may report altered sensation, sharp or shooting pain, and hypersensitivity to temperature, which can interfere with routine activities and overall treatment adherence. The severity and duration of symptoms vary depending on the type of chemotherapy, cumulative dose, and individual susceptibility, with some cases becoming chronic. Despite its clinical significance, effective preventive and disease-modifying treatments remain limited, making CIPN a critical area of ongoing research in oncology supportive care.

Get a Free sample for the Chemotherapy-Induced Peripheral Neuropathy Market Report @ Chemotherapy-Induced Peripheral Neuropathy Treatment Market

Key Factors in Chemotherapy-Induced Peripheral Neuropathy Therapeutics Market

• Rising Cancer Incidence and Chemotherapy Use

The increasing global burden of cancer and widespread use of neurotoxic chemotherapy agents are key drivers contributing to the growing prevalence of Chemotherapy-Induced Peripheral Neuropathy, thereby boosting demand for effective treatments.

• High Prevalence and Chronic Nature of CIPN

A significant proportion of patients undergoing chemotherapy develop CIPN, with symptoms often persisting long after treatment, creating a sustained need for long-term therapeutic management.

• Limited Treatment Options and Unmet Needs

The lack of approved preventive therapies and limited effective treatment options for CIPN highlight a major unmet medical need, encouraging the development of novel and targeted therapies.

• Advancements in Mechanism-Based Drug Development

Increasing research into the underlying mechanisms such as nerve damage, oxidative stress, and neuroinflammation is driving the development of innovative therapies targeting the root causes of CIPN.

• Growing Focus on Supportive Oncology Care

With improving cancer survival rates, there is a stronger emphasis on managing treatment-related side effects like CIPN, leading to increased adoption of supportive care therapies.

• Expansion of Clinical Trials and R&D Investments

Rising investments in research and an expanding number of clinical trials are accelerating the development of new therapeutic candidates for CIPN.

• Improved Healthcare Access and Awareness

Enhanced healthcare infrastructure and growing awareness among healthcare professionals and patients are facilitating early diagnosis and better management of CIPN.

• Opportunities in Emerging Markets

Increasing healthcare expenditure and expanding oncology care services in emerging regions are expected to create significant growth opportunities in the CIPN therapeutics market.

Chemotherapy-Induced Peripheral Neuropathy Epidemiology Segmentation in the 7MM

The Chemotherapy-Induced Peripheral Neuropathy Market Report proffers epidemiological analysis for the study period 2022-2036 in the 7MM, segmented into-

• Total Chemotherapy-Induced Peripheral Neuropathy Incident Population
• Chemotherapy-Induced Peripheral Neuropathy Severity-specific Incident Population
• Chemotherapy-Induced Peripheral Neuropathy Incident Population by Cancer Type
• Total Chemotherapy-Induced Peripheral Neuropathy Treated Population

Download the report to understand which factors are driving Chemotherapy-Induced Peripheral Neuropathy Epidemiology trends @ Chemotherapy-Induced Peripheral Neuropathy Epidemiology Forecast

Chemotherapy-Induced Peripheral Neuropathy Market Recent Developments and Breakthroughs

• In March 2026, Institut de Cancérologie de l'Ouest initiated a study focusing on Chemotherapy-Induced Peripheral Neuropathy, a common and debilitating side effect of systemic chemotherapy, particularly associated with agents such as oxaliplatin and taxanes. The study highlights that approximately 30–40% of patients receiving long-term treatment with these neurotoxic agents develop CIPN. Clinically, CIPN primarily presents as a sensory neuropathy characterized by symptoms such as numbness, tingling, and occasionally burning or shooting pain, typically progressing in a “stocking and glove” distribution affecting both upper and lower extremities.
• In the same month, VM Therapeutics LLC conducted a study evaluating VMD-3866 gel, an investigational, non-opioid and non-NSAID topical therapy designed to manage CIPN-related pain. The study aims to assess the efficacy of VMD-3866 in alleviating pain symptoms in patients with CIPN, while also evaluating its safety profile and potential side effects.

Chemotherapy-Induced Peripheral Neuropathy Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential Chemotherapy-Induced Peripheral Neuropathy drugs recently launched in the Chemotherapy-Induced Peripheral Neuropathy market or expected to get launched during the study period. The analysis covers Chemotherapy-Induced Peripheral Neuropathy Market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share. The report also covers the Chemotherapy-Induced Peripheral Neuropathy Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Chemotherapy-Induced Peripheral Neuropathy Therapies and Companies

• WinSanTor Inc.: WST-057
• Algo Therapeutix: ATX01 10%
• Institut Cancerologie de l'Ouest: Capsaicin/Duloxetine
• Hoffmann-La Roche: Olesoxime (TRO19622)
• Ono Pharmaceutical Co., Ltd: ONO-2910

To know more about Chemotherapy-Induced Peripheral Neuropathy Companies working in the treatment market, visit @ Chemotherapy-Induced Peripheral Neuropathy Clinical Trials and Therapeutic Assessment

Chemotherapy-Induced Peripheral Neuropathy Market Drivers

• Increasing Global Cancer Burden

The rising incidence of cancer worldwide has led to a significant increase in the use of chemotherapy, particularly neurotoxic agents such as platinum compounds and taxanes. This directly contributes to the growing prevalence of Chemotherapy-Induced Peripheral Neuropathy, thereby driving demand for effective therapeutic interventions.

• High Prevalence of CIPN Among Chemotherapy Patients

A considerable proportion of patients undergoing chemotherapy develop CIPN, with many experiencing persistent or long-term symptoms. This high prevalence underscores the need for better treatment options and fuels market growth.

• Limited Approved Treatment Options

The absence of effective preventive therapies and the limited availability of approved treatments for CIPN create a substantial unmet medical need. This gap is encouraging pharmaceutical companies to invest in novel drug development and innovative treatment approaches.

• Growing Focus on Supportive Oncology Care

As cancer survival rates improve, there is an increasing emphasis on managing treatment-related side effects to enhance patients’ quality of life. This shift toward comprehensive supportive care is boosting the demand for CIPN therapeutics.

• Advancements in Research and Drug Development

Ongoing research targeting the underlying mechanisms of nerve damage, including neuroinflammation and oxidative stress, is leading to the development of new therapeutic candidates, thereby expanding the pipeline landscape.

• Improving Healthcare Infrastructure and Awareness

Enhanced access to healthcare services and growing awareness among healthcare professionals regarding early diagnosis and management of CIPN are contributing to higher treatment adoption rates.

• Emerging Market Opportunities

Expanding oncology care infrastructure, rising healthcare expenditure, and increasing patient awareness in emerging economies are expected to create significant growth opportunities in the Chemotherapy-Induced Peripheral Neuropathy therapeutics market.

Chemotherapy-Induced Peripheral Neuropathy Market Barriers

• Limited Approved Treatment Options

The therapeutic landscape for Chemotherapy-Induced Peripheral Neuropathy remains highly restricted, with very few approved drugs available, primarily focusing on symptomatic relief rather than disease modification.

• Lack of Preventive Therapies

There are currently no widely accepted or approved therapies for the prevention of CIPN, creating a significant gap in early intervention and risk mitigation strategies.

• Complex and Poorly Understood Pathophysiology

The multifactorial nature of CIPN, involving mechanisms such as oxidative stress, mitochondrial dysfunction, and nerve damage, complicates drug development and limits the success rate of novel therapeutics.

• Challenges in Clinical Trial Design

Variability in symptom presentation, lack of standardized endpoints, and reliance on patient-reported outcomes make it difficult to design robust and consistent clinical trials for CIPN therapies.

• High Failure Rate of Pipeline Candidates

Many investigational drugs targeting CIPN have failed to demonstrate significant efficacy in late-stage trials, discouraging investment and slowing pipeline advancement.

• Dose Modification Instead of Treatment Adoption

In clinical practice, oncologists often manage CIPN by reducing or discontinuing chemotherapy doses rather than prescribing additional therapies, limiting the uptake of CIPN-specific treatments.

• Low Awareness and Underdiagnosis

CIPN is often underreported or underestimated in clinical settings, leading to delayed diagnosis and reduced demand for targeted therapeutic interventions.

• Reimbursement and Pricing Challenges

Limited clinical evidence supporting strong efficacy outcomes may hinder favorable reimbursement decisions, impacting market access for emerging therapies.

• Competition from Generic and Supportive Care Therapies

The widespread use of low-cost generics and non-pharmacological approaches (such as physical therapy and supplements) poses a challenge to the adoption of novel, premium-priced therapies.

• Regulatory Uncertainty

The absence of well-defined regulatory pathways and validated biomarkers for CIPN adds complexity to drug approval processes, potentially delaying market entry for new treatments.

Scope of the Chemotherapy-Induced Peripheral Neuropathy Market Report

• Coverage- 7MM
• Study Period- 2022-2036
• Chemotherapy-Induced Peripheral Neuropathy Companies- Averitas Pharma (Grünenthal), Dogwood Therapeutics, AlgoTherapeutix, Sanodyne Therapeutics/Toray Industries, Sonnet BioTherapeutics, Asahi Kasei Pharma, WinSanTor, VM Therapeutics, Tarian Pharma, and others.
• Chemotherapy-Induced Peripheral Neuropathy Pipeline Therapies- WST-05, ATX01 10%, Capsaicin, Duloxetine, Olesoxime (TRO19622), ONO-2910, VMD-3866 Gel, Acupuncture, Leteprinim Potassium (Neotrofin), and others.
• Chemotherapy-Induced Peripheral Neuropathy Therapeutic Assessment: Chemotherapy-Induced Peripheral Neuropathy current marketed and emerging therapies
• Chemotherapy-Induced Peripheral Neuropathy Market Dynamics: Chemotherapy-Induced Peripheral Neuropathy market drivers and Chemotherapy-Induced Peripheral Neuropathy market barriers
• Chemotherapy-Induced Peripheral Neuropathy Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Chemotherapy-Induced Peripheral Neuropathy Unmet Needs, KOL’s views, Analyst’s views, Chemotherapy-Induced Peripheral Neuropathy Market Access and Reimbursement

Discover more about therapies set to grab the major Chemotherapy-Induced Peripheral Neuropathy Market Share @ Chemotherapy-Induced Peripheral Neuropathy Treatment Market

Table of Contents

1. Key Insights

2. Chemotherapy-Induced Peripheral Neuropathy Market Report Introduction

3. Chemotherapy-Induced Peripheral Neuropathy Executive Summary

4. Chemotherapy-Induced Peripheral Neuropathy Key Events

5. Chemotherapy-Induced Peripheral Neuropathy Epidemiology and Market Forecast Methodology

6. Chemotherapy-Induced Peripheral Neuropathy Market Overview at a Glance

7. Chemotherapy-Induced Peripheral Neuropathy Disease Background and Overview

8. Chemotherapy-Induced Peripheral Neuropathy Epidemiology and Patient Population

9. Chemotherapy-Induced Peripheral Neuropathy Patient Journey

10. Chemotherapy-Induced Peripheral Neuropathy Marketed Drugs

11. Chemotherapy-Induced Peripheral Neuropathy Emerging Drugs

12. Chemotherapy-Induced Peripheral Neuropathy: 7MM Analysis

13. Chemotherapy-Induced Peripheral Neuropathy Unmet Needs

14. Chemotherapy-Induced Peripheral Neuropathy SWOT Analysis

15. Chemotherapy-Induced Peripheral Neuropathy KOL Views

16. Chemotherapy-Induced Peripheral Neuropathy Market Access and Reimbursement

17. Appendix

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.